CXCR3 and neoplasm: Treatment with BLU9931, an FGFR4 inhibitor, attenuated tumor progression, and co-treatment with the CXCR3 inhibitor AMG487 further enhanced this inhibitory effect, highlighting the synergistic function of the two inhibitors (Fig. 7A).